Figure 4
Antitumor efficacy of IP-10 plasmid combined with gemcitabine in two murine models. Mice (ten mice per group, including normal saline, solid triangles, gemcitabine alone, open triangles, IP-10 plasmid alone, solid circles, IP-10 plasmid combined with gemcitabine, open circles) were treated with injection of IP-10 plasmid 100 μg (i. m.) twice weekly for 4 weeks and/or administration of gemcitabine i.p. cycled twice (10 mg/kg, on the days 14 and 21 after initial of IP-10 plasmid administration). Normal saline 0.1 ml was injected as control. The treatment started at day 7 after 1 × 106 hepatocarcinoma cells (A, C) or Lewis lung cancer cells (B, D) were injected subcutaneously into mice. Combined treatment with IP-10 plasmid and gemcitabine resulted in significant inhibition of tumor growth and longer life span versus other three controls.